• Login
    View Item 
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of ChristieCommunitiesTitleAuthorsIssue DateSubmit DateSubjectsThis CollectionTitleAuthorsIssue DateSubmit DateSubjects

    My Account

    LoginRegister

    Local Links

    The Christie WebsiteChristie Library and Knowledge Service

    Statistics

    Display statistics

    Fibrolamellar carcinoma: Challenging the challenge

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Authors
    Lamarca, Angela
    Frizziero, Melissa
    Fulton, Alexander
    McNamara, Mairead G
    Filobbos, R.
    Hubner, Richard A
    Wardell, Steve
    Valle, Juan W
    Affiliation
    Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, United Kingdom; Division Cancer Sciences, University of Manchester; Manchester, United Kingdom.
    Issue Date
    2020
    
    Metadata
    Show full item record
    Abstract
    Fibrolamellar carcinoma (FLC) is a rare and poorly understood malignancy, which seems to be more prevalent in young patients compared with conventional hepatocellular carcinoma (HCC). Performing prospective clinical trials recruiting patients diagnosed with FLC has proven challenging with scarce data available guiding clinical management. The use of a number of chemotherapy compounds in these patients, including cisplatin, epirubicin, 5-fluorouracil (5-FU) and recombinant interferon ?-2B (IFN-?-2B), has been reported in the literature, mainly in the form of case reports. The most promising systemic therapy tested so far is the combination of 5-FU infusion and 3-weekly IFN-?-2B, based on results from a phase II clinical trial. This article provides an overview of our own experience with this treatment schedule for patients with FLC, confirming its activity and treatment-derived benefit in the real world. Current challenges being faced by healthcare professionals treating patients with advanced FLC are discussed, especially the increasingly limited access to IFN-?-2B, which could compromise the access to an active therapy in the coming future, and the difficulties in the development of new treatment options for advanced FLC. Keywords: 5-FU; 5-fluorouracil treatment; Advanced; Chemotherapy; FLC; Fibrolamellar carcinoma; IFN; Interferon; Systemic therapy.
    Citation
    Lamarca A, Frizziero M, Fulton A, McNamara MG, Filobbos R, Hubner RA, et al. Fibrolamellar carcinoma: Challenging the challenge. European Journal of Cancer. 2020;137:144-7.
    Journal
    European Journal of Cancer
    URI
    http://hdl.handle.net/10541/623258
    DOI
    10.1016/j.ejca.2020.06.035
    PubMed ID
    32768872
    Additional Links
    https://dx.doi.org/10.1016/j.ejca.2020.06.035
    Type
    Article
    Language
    en
    ae974a485f413a2113503eed53cd6c53
    10.1016/j.ejca.2020.06.035
    Scopus Count
    Collections
    All Christie Publications

    entitlement

    Related articles

    • Successful Liver Transplantation of Recurrent Fibrolamellar Carcinoma following Clinical and Pathologic Complete Response to Triple Immunochemotherapy: A Case Report.
    • Authors: Kang S, Magliocca J, Sellers M, Roccaro G, Zheng W, Pectasides M, Draper A, Guadagno J, El-Rayes B, Akce M
    • Issue date: 2022
    • Hepatic arterial infusion chemotherapy in combination with pegylated interferon-α-2b for advanced hepatocellular carcinoma.
    • Authors: Okita K, Yamasaki T, Hamabe S, Saeki I, Harima Y, Terai S, Sakaida I
    • Issue date: 2012 Mar-Apr
    • Clinical pilot study of intrahepatic arterial chemotherapy with methotrexate, 5-fluorouracil, cisplatin and subcutaneous interferon-alpha-2b for patients with locally advanced hepatocellular carcinoma.
    • Authors: Urabe T, Kaneko S, Matsushita E, Unoura M, Kobayashi K
    • Issue date: 1998 Jan-Feb
    • Phase II trial of systemic continuous fluorouracil and subcutaneous recombinant interferon Alfa-2b for treatment of hepatocellular carcinoma.
    • Authors: Patt YZ, Hassan MM, Lozano RD, Brown TD, Vauthey JN, Curley SA, Ellis LM
    • Issue date: 2003 Feb 1
    • Similar effects of recombinant interferon-alpha-2b and natural interferon-alpha when combined with intra-arterial 5-fluorouracil for the treatment of advanced hepatocellular carcinoma.
    • Authors: Uka K, Aikata H, Takaki S, Miki D, Jeong SC, Hiramatsu A, Kodama H, Shirakawa H, Kawakami Y, Takahashi S, Toyota N, Ito K, Chayama K
    • Issue date: 2007 Nov
    DSpace software (copyright © 2002 - 2023)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.